Has Terri Jerkins, MD received payments from drug or device companies?

Yes. Drug and device makers reported $1,179,139 in general payments to Terri Jerkins, MD across 2,364 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Terri Jerkins, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Terri Jerkins, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Terri Jerkins, MD

Endocrinology, Diabetes & Metabolism · Nashville, TNNPI 1538147319

Payments from drug & device makers

$1,179,139in general payments, 2019–2025

Across 2,364 payments — averaging $498.79 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Novo Nordisk$355K
Novo Nordisk AS$326K
AbbVie$282K
Corcept Therapeutics$86K
AstraZeneca$51K
Bayer$36K
plus $43K from 50 others

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Novo Nordisk	424	$355,149
Novo Nordisk AS	792	$325,904
AbbVie	82	$282,408
Corcept Therapeutics	165	$85,532
AstraZeneca(2 entities)	112	$51,336
Bayer	75	$35,689
Johnson & Johnson	28	$21,743
Xeris Pharmaceuticals, Inc.	62	$5,590
Salix Pharmaceuticals, A Division Of Bausch Health US, LLC	13	$2,127
Abbott	74	$1,676
Amgen(2 entities)	85	$1,655
Insulet Corporation	67	$1,145
Sanofi-aventis U.S. LLC	32	$995
Lilly USA, LLC	51	$993
Novartis	36	$884
Dexcom, Inc.	28	$625
BETA Bionics, Inc.	20	$620
Mannkind Corporation	24	$443
Recordati_rare_diseases_inc.	8	$415
Tandem Diabetes Care, Inc.	14	$401
Astellas Pharma US Inc	7	$293
Boehringer Ingelheim	14	$286
Amarin Pharma, Inc.	19	$286
Ascensia Diabetes Care US Inc.	4	$263
Radius Health, Inc.	14	$241
Medtronic(2 entities)	10	$224
Cequr Corporation	2	$216
Esperion Therapeutics, Inc.	10	$206
Neurocrine Biosciences, Inc.	6	$184
Sequel Med Tech, LLC	6	$172
Merck	13	$168
Antares Pharma, Inc.	9	$162
Pfizer	9	$159
Nestle Healthcare Nutrition Inc.	5	$95
Ascendis Pharma Endocrinology Inc	4	$82
Lifescan, Inc.	4	$71
Clarus Therapeutics Inc.	5	$67
Madrigal Pharmaceuticals	2	$64
Shire North American Group Inc	4	$62
Eisai Inc.	2	$56
Chiesi USA, Inc.	2	$53
Evoke Pharma, Inc.	3	$49
Amphastar Pharmaceuticals, Inc.	2	$43
Endo Pharmaceuticals Inc.	2	$37
Kyowa Kirin, Inc.	2	$35
Biohaven Pharmaceutical Holding Company Ltd.	2	$33
Nevro Corp.	1	$31
Companion Medical, Inc.	1	$28
Biohaven Pharmaceuticals, Inc.	1	$23
Amryt Pharma Holdings Ltd	1	$22
Regeneron Healthcare Solutions, Inc.	1	$21
GSK	1	$18
Acella Pharmaceuticals, LLC	1	$17
Ultragenyx Pharmaceutical Inc.	1	$17
Idorsia Pharmaceuticals US Inc	1	$14
Amneal Pharmaceuticals LLC	1	$12

How this compares

$1,179,139 in reported general payments places this provider in the 90th percentile of 130 endocrinology, diabetes & metabolism providers in Tennessee.

See all endocrinology, diabetes & metabolism providers in Tennessee →

Medicare billing

Part B allowed, 2024

$76,212

Medicare patients

242

Services billed

710

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other endocrinology, diabetes & metabolism in Nashville

Stephen SharpNashville$25.9M
Kathryn DahirNashville$11M
Craig WierumNashville$1.7M
Shichun BaoNashville$735K
Michael MayNashville$689K
Michael CarlsonNashville$381K
Rodney SnowNashville$188K
Kevin NiswenderNashville$100K
Howard BaumNashville$81K
Annis MarneyNashville$26K

See the full list for Tennessee →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →